poisar

Stocks · News reference

Clover Health Investments Raises FY2026 Sales Guidance from $2.810B-$2.920B to $2.920B-$3.000B vs $2.910B Est

Benzinga Newsdesk

Clover Health Investments (NASDAQ:CLOV) raises FY2026 sales outlook from $2.810 billion-$2.920 billion to $2.920 billion-$3.000 billion vs $2.910 billion estimate.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CLOV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. to Its Board of Directors

    Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D. to its Board of Directors, effective immediately. Senator Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. The appointments fill two board vacancies and bring the board to nine directors. Both appointees bring extensive experience in healthcare policy, Medicare Advantage, clinical practice, and business strategy.

    CLOV
  2. SEC EDGAR

    8-K/A filing — CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

    Filed: 2026-09-25 AccNo: 0001801170-26-000232 Size: 159 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    CLOV
  3. Na

    Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors

    Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., to its Board of Directors, effective immediately. Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. Both appointments bring complementary expertise in healthcare policy, Medicare Advantage, clinical practice, and business strategy to strengthen the company's governance and execution.

    CLOV
  4. SEC EDGAR

    8-K filing — CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

    Filed: 2026-09-24 AccNo: 0001801170-26-000229 Size: 157 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    CLOV